Tripotassium hexacyanoferrate

Endpoint summary

Description of key information

An acute oral and an acute dermal toxicity study are available for substance analogue potassium ferrocyanide. Testing was performed similar to or according to the respective OECD test guidelines. Both the oral and the dermal LD50 values exceed 2000 mg/kg bw. These results are read across to potassium ferricyanide, the read across hypothesis is attached in IUCLID Section 13.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Justification for type of information:

Based on similar metal-cyanide complex species, the source substance sodium ferrocyanide and the target substance potassium ferricyanide can be regarded as analogues, which implies that data from sodium ferrocyanide can be read-across to the target substance potassium ferricyanide. The read across rationale is attached in 'Attached justification'.

Reason / purpose for cross-reference:

read-across source

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 5 110 mg/kg bw

Based on:

test mat.

Mortality:

No deaths occurred during the study.

Clinical signs:

other: In all animals diarrhoea was observed on the first day (day 1) after application.

Gross pathology:

No data

Other findings:

None.

Interpretation of results:

GHS criteria not met

Conclusions:

In an acute oral toxicity study with male and female rats, performed equivalent or similar to OECD 401 guideline, the LD50 of sodium ferrocyanide was calculated to be >5110 mg/kg. This result is read across to potassium ferricyanide.

Executive summary:

In an acute oral toxicity study with sodium ferrocyanide, performed comparable to OECD test guideline 401, male and female rats were exposed to 5110 mg/kg via gavage. No deaths occurred during the study. In all animals diarrhoea was observed on the first day (day 1) after application. The LD50 was determined to be >5110 mg/kg. The result is read across to potassium ferricyanide.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

5 110 mg/kg bw

Quality of whole database:

A reliable study was used (Klimisch 2).

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Justification for type of information:

Based on identical metal-cyanide complex species, the source substance sodium ferrocyanide and the target substance potassium ferricyanide can be regarded as analogues, which implies that data from sodium ferrocyanide can be read-across to the target substance potassium ferricyanide. The complete rationale is attached in 'Attached justification'.

Reason / purpose for cross-reference:

read-across source

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

One female was found dead on day 2 of treatment.

Clinical signs:

other: Chromodacryorrhoea and/or piloerection were noted in the majority of animals between days 1 and 3. Hunched posture was seen in one male on Day 1 and flat posture was seen in one male on day 1. The animal found dead showed hunched posture, piloerection, ch

Gross pathology:

Macroscopic post mortem examination of the animal that died during the study and of the animals surviving to the end of the study did not reveal any abnormalities. Pelvic dilation of the kidneys (one male), is commonly noted among rats of this age and strain and were therefore considered not toxicologically significant.

Other findings:

Scales were seen in the treated skin-area of one animal during the observation period.

Interpretation of results:

GHS criteria not met

Conclusions:

In an acute dermal toxicity study with rats, performed according to OECD/EC test guideline, an LD50 >2000 mg/kg bw was determined for sodium ferrocyanide. This result is read across to potassium ferricyanide.

Executive summary:

An acute dermal toxicity test was performed according to OECD/EC guideline and GLP principles with sodium ferrocyanide. Five male and five female rats were exposed to 2000 mg/kg bw for 24 hours. One female was found dead on day 2, this animal showed hunched posture, piloerection, chromodacryorrhoea and ptosis on day 1. In the majority of the other rats, clinical signs such as chromodacryorrhoea and/or piloerection were noted between days 1 and 3. Hunched posture was seen in one male on day 1 and flat posture was seen in one male on day 1. No changes in body weight gain were noted, no abnormalities were found after nacroscopical examination. Scales were seen in the treated skin-area of one animal during the observation period. Based on these data, the test substance is not classified for acute dermal toxicity. This result is read across to potassium ferricyanide.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Quality of whole database:

A reliable study was used (Klimisch 1).

Additional information

In an acute oral toxicity study, performed with substance analogue sodium ferrocyanide and comparable to OECD test guideline 401, male and female rats were exposed to 5110 mg/kg via gavage. No deaths occurred during the study. In all animals diarrhoea was observed on the first day (day 1) after application. The LD50 was determined to be >5110 mg/kg bw.

An acute dermal toxicity test was performed with substance analogue sodium ferrocyanide and according to OECD/EC guideline and GLP principles. Five male and five female rats were exposed to 2000 mg/kg bw for 24 hours. One female was found dead on day 2, this animal showed hunched posture, piloerection, chromodacryorrhoea and ptosis on day 1. In the majority of the other rats, clinical signs such as chromodacryorrhoea and/or piloerection were noted between days 1 and 3. Hunched posture was seen in one male on day 1 and flat posture was seen in one male on day 1. No changes in body weight gain were noted, no abnormalities were found after nacroscopical examination. Scales were seen in the treated skin-area of one animal during the observation period.

The results are read across to potassium ferricyanide, the read across hypothesis is attached in IUCLID Section 13.

Justification for classification or non-classification

Based on the available studies, potassium ferricyanide is not classified for acute toxicity according to the CLP Regulation (No) EC 1272/2008.